Turbidimetric assay to help monitor Pancreatic Exocrine Insufficiency
21. Aug 2020 |
3 min read
The newly released CE marked immunoassay BÜHLMANN fPELA® turbo is an immuno turbidimetric faecal pancreatic elastase assay for simplified quantification of human pancreatic elastase as an aid in the determination of pancreatic exocrine insufficiency (PEI).
BÜHLMANN fPELA® turbo provides a flexible and random-access application for most available clinical chemistry platforms. With the dramatically reduced hands-on time required, this assay allows the pancreatic elastase results from human stool samples to be processed very quickly.
PEI can be caused by several underlying disorders, like chronic pancreatitis, pancreatic cancer, diabetes mellitus, and Inflammatory Bowel Disease (IBD). Consequences include diarrhea, malnutrition, and reduced Quality of Life. Hence determination of PEI and patient targeted treatment are of high importance a successful clinical outcome.
Same extraction buffer system for both pancreatic elastase and faecal calprotectin (BÜHLMANN fCAL® turbo)
Gentian has, in cooperation with BÜHLMANN, successfully delivered the BÜHLMANN fCAL® turbo to the market since 2016. The BÜHLMANN fCAL® turbo is the highest level automated faecal IVD test system for Inflammatory Bowel Disease (IBD) and screening of IBD vs Irritable Bowel Syndrome (IBS) on the market.
To increase diagnostic efficiency BÜHLMANN fPELA® turbo and BÜHLMANN fCAL® turbo use the same extraction buffer system, CALEX® Cap, which allows the quantitation of both analytes from the same sample preparation. Additionally, there is also an analytical and clinical advantage of the combination of p-Elastase with faecal calprotectin in the same sample. PEI and IBD may have similar symptom presentation, and therefore represents an ideal combination of markers for bowel inflammation.